Browse Studies — Arctuva

Phase 1

Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial…

Heterozygous Familial HypercholesterolemiaPremature Coronary Heart Disease

Estimated

~$10 – $8,750

Verve Therapeutics, Inc.NCT06164730

Phase 1

Thiamine Intervention and Cognition in Older Adults Undergoing Coronary Artery Bypass Grafting - A Randomized Clinical Trial.

The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) pat…

Coronary Heart DiseaseCoronary Artery Bypass Grafting

Estimated

~$10 – $6,250

University of California, Los AngelesNCT06326996

Observational

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

Developed nations worldwide are currently enduring a health crisis, as chronic diseases continue to decrease quality of life and promote additional disease sta…

ObesityHyperlipidemiasPolycystic Ovary Syndrome+6 more

Estimated

~$10 – $7,500

West Virginia School of Osteopathic MedicineNCT06049420

Observational

Ultra-High Resolution Computed Tomography (CT) vs. Conventional CT for Detecting Obstructive Coronary Artery Disease (CAD) The CORE-COMPARE Pilot Study

The utility of Ultra High-Resolution Computed Tomography (UHR-CT) compared to conventional CT in all-comers (i.e., a generally lower-risk population) remains u…

Coronary Heart Disease (CHD)

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT06170541